Research Articles | Page 31 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Transfusion Support of Patients with Myelodysplastic Syndromes Dec 2023 Clinics in Laboratory Medicine Myelodysplastic Syndromes (MDS)
Morphologic Characteristics of Myelodysplastic Syndromes Dec 2023 Clinics in Laboratory Medicine Myelodysplastic Syndromes (MDS)
Diagnosis and Classification of Myelodysplastic Syndromes with Mutated TP53 Dec 2023 Clinics in Laboratory Medicine Myelodysplastic Syndromes (MDS)
Acute Myeloid Leukemia Arising from Myelodysplastic Syndromes Dec 2023 Clinics in Laboratory Medicine Myelodysplastic Syndromes (MDS)
Treatment Considerations of Myelodysplastic Syndromes/Neoplasms for Pathologists Dec 2023 Clinics in Laboratory Medicine Myelodysplastic Syndromes (MDS)
Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study Dec 2023 Leukemia Aplastic Anemia
Haploidentical Transplant with Post-Transplant Cyclophosphamide for Acute Myeloid Leukaemia and Myelodysplastic Syndromes Patients: The Role of Previous Lines of Therapy Jan 2024 Mediterranean Journal of Hematology and Infectious Diseases Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Paroxysmal Nocturnal Hemoglobinuria Jan 2024 StatPearls Paroxysmal Nocturnal Hemoglobinuria (PNH)
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial Jan 2024 Lancet Hematology Myelodysplastic Syndromes (MDS)
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study Jan 2024 Lancet Hematology Myelodysplastic Syndromes (MDS)